Liraglutide and renal outcomes in type 2 diabetes

New England Journal of Medicine

Volumn 377, Issue 22, 2017, Pages 2195-

  Tonneijck, Lennart ^a   Van Raalte, Daniël H ^a   Muskiet, Marcel H A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; ANTIDIABETIC AGENT;

ALBUMINURIA; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; KIDNEY;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LIRAGLUTIDE;

EID: 85038423099     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1713042     Document Type: Letter

References (5)

1. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-48.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-22.
3. Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Heerspink HJ, van Raalte DH. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 2015; 3: 367-81.
4. Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 2017; 13: 605-28.
5. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-To-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 610-21.